Reactive oxygen species scavenging and inflammation mitigation enabled by biomimetic prussian blue analogues boycott atherosclerosis
Tóm tắt
As one typical cardiovascular disease, atherosclerosis severely endanger people’ life and cause burden to people health and mentality. It has been extensively accepted that oxidative stress and inflammation closely correlate with the evolution of atherosclerotic plaques, and they directly participate in all stages of atherosclerosis. Regarding this, anti-oxidation or anti-inflammation drugs were developed to enable anti-oxidative therapy and anti-inflammation therapy against atherosclerosis. However, current drugs failed to meet clinical demands. Nanomedicine and nanotechnology hold great potential in addressing the issue. In this report, we engineered a simvastatin (Sim)-loaded theranostic agent based on porous manganese-substituted prussian blue (PMPB) analogues. The biomimetic PMPB carrier could scavenge ROS and mitigate inflammation in vitro and in vivo. Especially after combining with Sim, the composite Sim@PMPB NC was expected to regulate the processes of atherosclerosis. As well, Mn2+ release from PMPB was expected to enhance MRI. The composite Sim@PMPB NC performed the best in regulating the hallmarks of atherosclerosis with above twofold decreases, typically such as oxidative stress, macrophage infiltration, plaque density, LDL internalization, fibrous cap thickness and foam cell birth, etc. Moreover, H2O2-induced Mn2+ release from PMPB NC in atherosclerotic inflammation could enhance MRI for visualizing plaques. Moreover, Sim@PMPB exhibited high biocompatibility according to references and experimental results. The biomimetic Sim@PMPB theranostic agent successfully stabilized atherosclerotic plaques and alleviated atherosclerosis, and also localized and magnified atherosclerosis, which enabled the monitoring of H2O2-associated atherosclerosis evolution after treatment. As well, Sim@PMPB was biocompatible, thus holding great potential in clinical translation for treating atherosclerosis.
Tài liệu tham khảo
Hansson GK. Mechanisms of disease—inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352(16):1685–95.
Ross R. Mechanisms of disease—atherosclerosis—an inflammatory disease. N Engl J Med. 1999;340(2):115–26.
Lusis AJ. Atherosclerosis. Nature. 2000;407(6801):233–41.
Wei X, Ying M, Dehaini D, Su Y, Kroll AV, Zhou J, et al. Nanoparticle functionalization with platelet membrane enables multifactored biological targeting and detection of atherosclerosis. ACS Nano. 2018;12(1):109–16.
Moore KJ, Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell. 2011;145(3):341–55.
Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011;473(7347):317–25.
Berliner JA, Navab M, Fogelman AM, Frank JS, Demer LL, Edwards PA, et al. Atherosclerosis - basic mechanisms - oxidation, inflammation, and genetics. Circulation. 1995;91(9):2488–96.
Chen K, Keaney JF Jr. Evolving concepts of oxidative stress and reactive oxygen species in cardiovascular disease. Curr Atheroscler Rep. 2012;14(5):476–83.
Nowak WN, Deng J, Ruan XZ, Xu Q. Reactive oxygen species generation and atherosclerosis. Arterioscler Thromb Vasc Biol. 2017;37(5):E41–52.
Wang Y, Li L, Zhao W, Dou Y, An H, Tao H, et al. Targeted therapy of atherosclerosis by a broad-spectrum reactive oxygen species scavenging nanoparticle with intrinsic anti-inflammatory activity. ACS Nano. 2018;12(9):8943–60.
Libby P. Inflammation in atherosclerosis. Nature. 2002;420(6917):868–74.
Hsiai T, Berliner JA. Oxidative stress as a regulator of murine atherosclerosis. Curr Drug Targets. 2007;8(12):1222–9.
Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol. 2011;12(3):204–12.
Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105(9):1135–43.
Kattoor AJ, Pothineni NVK, Palagiri D, Mehta JL. Oxidative stress in atherosclerosis. Curr Atheroscler Rep. 2017;19(11):42.
Grebenyuk AN, Gladkikh VD. Modern condition and prospects for the development of medicines towards prevention and early treatment of radiation damage. Biol Bull. 2019;46(11):1540–55.
Hansson GK, Libby P. The immune response in atherosclerosis: A double-edged sword. Nat Rev Immunol. 2006;6(7):508–19.
Chan CKW, Zhang L, Cheng CK, Yang H, Huang Y, Tian XY, et al. Recent advances in managing atherosclerosis via nanomedicine. Small. 2018;14(4):1702793.
Bejarano J, Navarro-Marquez M, Morales-Zavala F, Morales JO, Garcia-Carvajal I, Araya-Fuentes E, et al. Nanoparticles for diagnosis and therapy of atherosclerosis and myocardial infarction: evolution toward prospective theranostic approaches. Theranostics. 2018;8(17):4710–32.
Zhang J, Zu Y, Dhanasekara CS, Li J, Wu D, Fan Z, et al. Detection and treatment of atherosclerosis using nanoparticles. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2017;9(1):e1412.
Kim M, Sahu A, Kim GB, Nam GH, Um W, Shin SJ, et al. Comparison of in vivo targeting ability between cRGD and collagen-targeting peptide conjugated nano-carriers for atherosclerosis. J Control Release. 2018;269:337–46.
Su T, Wang Y-B, Han D, Wang J, Qi S, Gao L, et al. Multimodality imaging of angiogenesis in a rabbit atherosclerotic model by GEBP11 peptide targeted nanoparticles. Theranostics. 2017;7(19):4791–804.
Ruehm SG, Corot C, Vogt P, Kolb S, Debatin JF. Magnetic resonance imaging of atherosclerotic plaque with ultrasmall superparamagnetic particles of iron oxide in hyperlipidemic rabbits. Circulation. 2001;103(3):415–22.
Zhao J, Gao W, Cai X, Xu J, Zou D, Li Z, et al. Nanozyme-mediated catalytic nanotherapy for inflammatory bowel disease. Theranostics. 2019;9(10):2843–55.
Zhao J, Cai X, Gao W, Zhang L, Zou D, Zheng Y, et al. Prussian blue nanozyme with multienzyme activity reduces colitis in mice. ACS Appl Mater Interfaces. 2018;10(31):26108–17.
Zhang W, Hu S, Yin J-J, He W, Lu W, Ma M, et al. Prussian blue nanoparticles as multienzyme mimetics and reactive oxygen species scavengers. J Am Chem Soc. 2016;138(18):5860–5.
Feng L, Dou C, Xia Y, Li B, Zhao M, Yu P, et al. Neutrophil-like cell-membrane-coated nanozyme therapy for ischemic brain damage and long-term neurological functional recovery. ACS Nano. 2021;15(2):2263–80.
Hou W, Ye C, Chen M, Gao W, Xie X, Wu J, et al. Excavating bioactivities of nanozyme to remodel microenvironment for protecting chondrocytes and delaying osteoarthritis. Bioact Mater. 2021;6(8):2439–51.
Tan J, Duan X, Zhang F, Ban X, Mao J, Cao M, et al. Theranostic nanomedicine for synergistic chemodynamic therapy and chemotherapy of orthotopic glioma. Adv Sci. 2020;7(24):2003036.
Chen Q, Liang C, Sun XQ, Chen JW, Yang ZJ, Zhao H, et al. H2O2-responsive liposomal nanoprobe for photoacoustic inflammation imaging and tumor theranostics via in vivo chromogenic assay. Proc Natl Acad Sci U S A. 2017;114(21):5343–8.
Jin X, Qu H, Zhu C, Jing L, Yu T. Advances of function of Prussian blue nano-materials in cancer diagnosis and therapy. J Biomed Eng. 2016;33(6):1209–13.
Cai X, Ma M, Chen H, Shi J, Ma M, Chen H, et al. Progress of applications of the Prussian blue in cancer diagnosis and therapy. Sci Technol Rev. 2016;34(2):18–26.
Zhang K, Fang Y, He Y, Yin H, Guan X, Pu Y, et al. Extravascular gelation shrinkage-derived internal stress enables tumor starvation therapy with suppressed metastasis and recurrence. Nat Commun. 2019;10:5380.
Cai X, Zhang K, Xie X, Zhu X, Feng J, Jin Z, et al. Self-assembly hollow manganese Prussian white nanocapsules attenuate Tau-related neuropathology and cognitive decline. Biomaterials. 2020;231:119678.
Zhang K, Tu M, Gao W, Cai X, Song F, Chen Z, et al. Hollow prussian blue nanozymes drive neuroprotection against ischemic stroke via attenuating oxidative stress, counteracting inflammation, and suppressing cell apoptosis. Nano Lett. 2019;19(5):2812–23.
Xie X, Zhao J, Gao W, Chen J, Hu B, Cai X, et al. Prussian blue nanozyme-mediated nanoscavenger ameliorates acute pancreatitis via inhibiting TLRs/NF-kappa B signaling pathway. Theranostics. 2021;11(7):3213–28.
Guan X, Yin H-H, Xu X-H, Xu G, Zhang Y, Zhou B-G, et al. Tumor metabolism-engineered composite nanoplatforms potentiate sonodynamic therapy via reshaping tumor microenvironment and facilitating electron-hole pairs’ separation. Adv Funct Mater. 2020;30(27):2000326.
Yin Y, Jiang X, Sun L, Li H, Su C, Zhang Y, et al. Continuous inertial cavitation evokes massive ROS for reinforcing sonodynamic therapy and immunogenic cell death against breast carcinoma. Nano Today. 2021;36:101009.
Zhang K, Cheng Y, Ren W, Sun L, Liu C, Wang D, et al. Coordination-responsive longitudinal relaxation tuning as a versatile MRI sensing protocol for malignancy targets. Adv Sci. 2018;5(9):1800021.
Mi P, Kokuryo D, Cabral H, Wu H, Terada Y, Saga T, et al. A pH-activatable nanoparticle with signal-amplification capabilities for non-invasive imaging of tumour malignancy. Nat Nanotechnol. 2016;11(8):724–30.